Hamilton Thorne, Inc. Receives Approval on Warrant Extension

BEVERLY, MA and TORONTO--(Marketwire - April 27, 2011) -

Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems for the regenerative medicine, developmental biology, stem cell research and fertility markets, today announced that, further to its news release issued on April 25, 2011, the Company has received approval from the TSX Venture Exchange (the “TSXV”) to extend the term of 5,500,005 common share purchase warrants originally issued on October 28, 2009 (the “2009 Warrants”) as part of a brokered private placement of its securities. The expiry date of the 2009 Warrants has been extended from April 28, 2011 to October 28, 2012. All other terms of the 2009 Warrants, including the exercise price of Cdn$0.60 per common share, remain unchanged. Please see the news release issued on November 2, 2009 for further details on the 2009 Warrants.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading provider of advanced laser systems for the regenerative medicine, stem cell research and fertility markets. Hamilton Thorne’s lead products, the ZILOS-tk™ and XYClone® laser systems, attach to standard inverted microscopes and operate as robotic micro-surgeons, significantly reducing time and increasing efficiency in key in-vitro fertilization, stem cell, and regenerative medical research applications. The new Staccato™ and Stiletto™ laser systems are designed to broaden the Company’s markets and offer significant advantages to developmental biology, cancer research and advanced cell biology researchers.

Hamilton Thorne’s growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, McGill University, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University, and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: stem cell stem cell research regenerative medicine advanced cell biology fertility lasers IVF